Roche: CT-388 Dual GLP1-GIP Receptor Agonist Clinically Improves Weight Loss
Patients who received CT-388 had an average placebo-adjusted weight loss of 18.8%. CT-388 is well tolerated with only mild to ...
Tag: carmot therapeutics
Patients who received CT-388 had an average placebo-adjusted weight loss of 18.8%. CT-388 is well tolerated with only mild to ...